Organoids are driven by stem cells to form self-renewing tissues with a 3D multicellular structure with histological characteristics of the source organ. Organoids can differentiate into organ-specific cell types and reproduce part of the function and spatial structure of corresponding organs. With the rapid development of organoid technology, organoids have been used in various research fields. To date, organoids have been used on a variety of tissues, including the gut, breast, liver, pancreas, heart, kidney, prostate, lung, retina, and brain, et al. Tumor organoids can better simulate the tumour environment in vivo, which undoubtedly provides a better solution for tumour research, drug screening, regenerative medicine and other fields at the animal and cellular level.
In cancer research, it has always been difficult to construct human tumour cancer models that can accurately simulate tumour heterogeneity, cancer progression and cancer metastasis. The difference between tumour tissue and tumour organoids still exists due to the change of culture conditions. For example, some factors in the medium may affect the gene expression profile of the organoids. There is no immune response in many tumour organoid models, especially in most of the current Patient-Derived Organoid models. In addition, most of the organoids are not passed on indefinitely. Those problems are still a pose a major challenge for organoid applications in cancer research, while new and improved materials or 3D scaffold-based culture techniques are still lacking.
This Research Topic welcomes submissions related, but not limited to, the following areas:
• New approaches for tumour organoid generation
• Novel 3D organoid culture techniques and new materials
• Engineering of 3D organoids: new strategies for engineering organoids with functional vasculature; new platforms or microfluidic devices for organoid monitoring
• Novel tumour organoid models for drug screening & new organoid models with the characteristics of tumour cell composition and/or that mimic tumour microenvironment for drug evaluation
• Organoid models for cancer immunotherapy and development of organoid models for investigating tumour cell - immune cell interactions
• Tumour organoids for personalized medicine and targeted therapy
Organoids are driven by stem cells to form self-renewing tissues with a 3D multicellular structure with histological characteristics of the source organ. Organoids can differentiate into organ-specific cell types and reproduce part of the function and spatial structure of corresponding organs. With the rapid development of organoid technology, organoids have been used in various research fields. To date, organoids have been used on a variety of tissues, including the gut, breast, liver, pancreas, heart, kidney, prostate, lung, retina, and brain, et al. Tumor organoids can better simulate the tumour environment in vivo, which undoubtedly provides a better solution for tumour research, drug screening, regenerative medicine and other fields at the animal and cellular level.
In cancer research, it has always been difficult to construct human tumour cancer models that can accurately simulate tumour heterogeneity, cancer progression and cancer metastasis. The difference between tumour tissue and tumour organoids still exists due to the change of culture conditions. For example, some factors in the medium may affect the gene expression profile of the organoids. There is no immune response in many tumour organoid models, especially in most of the current Patient-Derived Organoid models. In addition, most of the organoids are not passed on indefinitely. Those problems are still a pose a major challenge for organoid applications in cancer research, while new and improved materials or 3D scaffold-based culture techniques are still lacking.
This Research Topic welcomes submissions related, but not limited to, the following areas:
• New approaches for tumour organoid generation
• Novel 3D organoid culture techniques and new materials
• Engineering of 3D organoids: new strategies for engineering organoids with functional vasculature; new platforms or microfluidic devices for organoid monitoring
• Novel tumour organoid models for drug screening & new organoid models with the characteristics of tumour cell composition and/or that mimic tumour microenvironment for drug evaluation
• Organoid models for cancer immunotherapy and development of organoid models for investigating tumour cell - immune cell interactions
• Tumour organoids for personalized medicine and targeted therapy